Abstract
Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemether-lumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.
| Original language | English |
|---|---|
| Pages (from-to) | 964-967 |
| Number of pages | 4 |
| Journal | American Journal of Tropical Medicine and Hygiene |
| Volume | 61 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1999 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver